No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
624 |
4. Check minimum number of eventsNone |
624 |
5. Include endpointsNone |
624 |
6. Filter based on genotype QC (FinnGen only) |
624 |
Control definitions (FinnGen only)
- Control exclude
- H7_OCUMUSCLE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H49
- Name in latin
- Paresis/paralysis nervi oculomotorii
Similar endpoints
↥List of similar endpoints to
Third [oculomotor] nerve palsy
based on the number of shared cases.
Similar with more cases:
- Paralytic strabismus
- Strabismus
- Disorders of ocular muscles, binocular movement, accommodation and refraction
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4483 | 2283 | 2171 |
| Only index persons | 3953 | 2021 | 1932 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.06 | 0.07 | 0.06 |
| Only index persons | 0.07 | 0.07 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 65.73 | 66.58 | 64.73 |
| Only index persons | 64.72 | 65.45 | 63.95 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 624 | 326 | 298 |
| Unadjusted period prevalence (%) | 0.12 | 0.11 | 0.13 |
| Median age at first event (years) | 62.15 | 58.96 | 65.64 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 571
- Matched controls
- 5708
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
+∞
323.0
571
*
H53.2
ICD-10 Finland
Diplopia
50.1
159.1
192
57
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
754.6
69.6
67
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
8.2
56.4
137
212
AA1AD
NOMESCO Finland
CT of head and brain
4.4
54.1
262
922
XCW99
NOMESCO Finland
Other investigative procedure of eye
5.8
46.6
149
329
D32.02
ICD-10 Finland
Benign tumor of the meninges at the base of the brain
54.0
45.7
54
11
XCK00
NOMESCO Finland
Perimetry
7.2
45.1
118
199
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.3
38.9
170
513
H49.1
ICD-10 Finland
Fourth [trochlear] nerve palsy
357.2
34.3
34
*
H02.4
ICD-10 Finland
Ptosis of eyelid
9.5
33.5
71
84
I67.1
ICD-10 Finland
Cerebral aneurysm, nonruptured
15.9
33.5
55
38
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
10.4
28.1
56
59
TAB00
NOMESCO Finland
Lumbar puncture
7.6
27.4
66
96
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
17.8
25.7
40
24
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.6
25.2
93
230
R51.80
ICD-10 Finland
Headache
3.4
23.1
127
444
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.9
21.7
97
285
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
21.7
18.8
27
13
AAC00
NOMESCO Finland
Ligature of intracranial aneurysm
15.7
18.6
30
20
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
+∞
17.8
17
*
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
13.8
17.1
29
22
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
13.8
17.1
29
22
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.0
16.9
110
425
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
10.5
16.6
32
32
B01AC04
ATC
clopidogrel; oral
2.6
16.2
131
579
PA2BD
NOMESCO Finland
Extensive CT angiography of brain
8.1
16.1
36
47
H50.2
ICD-10 Finland
Vertical strabismus
+∞
15.7
15
*
H50.1
ICD-10 Finland
Divergent concomitant strabismus
+∞
15.7
15
*
CE2W4
NOMESCO Finland
Eye movement mapping
164.2
15.5
16
*
PA2CC
NOMESCO Finland
Cerebral very extensive angiography with X-ray
16.6
15.4
24
15
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
3.5
15.3
74
231
A10AC01
ATC
insulin (human); parenteral (insulins and analog. for injection, intermediate-acting)
3.5
15.2
75
238
A10AE04
ATC
insulin glargine; parenteral
3.2
14.9
84
294
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
43.6
14.2
17
*
A10AB01
ATC
insulin (human); parenteral (insulins and analog. for injection, fast-acting)
5.5
13.9
41
79
G70.0
ICD-10 Finland
Myasthenia gravis
54.7
13.9
16
*
H02AB09
ATC
hydrocortisone; systemic
7.5
12.9
30
42
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
3.7
12.7
57
167
I60.3
ICD-10 Finland
Subarachnoid haemorrhage from posterior communicating artery
132.7
12.5
13
*
G51.0
ICD-10 Finland
Bell palsy
6.2
12.4
33
56
A10AB04
ATC
insulin lispro; parenteral (insulins and analog. for injection, fast-acting)
5.7
12.3
35
65
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.3
12.2
123
602
XCK10
NOMESCO Finland
Photography of fundus of eye
2.8
12.2
82
322
E23.00
ICD-10 Finland
Panhypopituitarism
21.8
12.1
17
8
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
13.8
12.0
20
15
A10AA01
ATC
NA
6.4
12.0
31
51
PA6BD
NOMESCO Finland
Extensive CT of neck arteries
4.2
12.0
45
113
H53.4
ICD-10 Finland
Visual field defects
6.9
11.9
29
44
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.9
11.9
252
1677
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.1
11.8
68
242
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
4.8
11.6
38
83
H49.9
ICD-10 Finland
Paralytic strabismus, unspecified
+∞
11.5
11
*
PA2BC
NOMESCO Finland
Cerebral extensive angiography with X-ray
9.2
11.3
23
26
A10AA02
ATC
NA
4.8
11.3
37
81
H3603, E103
ICD-10 Finland
NA
11.5
11.1
20
18
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.3
10.9
55
178
N07AA02
ATC
pyridostigmine; systemic
21.9
10.7
15
7
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
14.5
10.5
17
12
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
10.4
10
*
CEC30
NOMESCO Finland
Resection of extraocular muscle
+∞
10.4
10
*
CEC00
NOMESCO Finland
Recession of extraocular muscle
+∞
10.4
10
*
CBJ10
NOMESCO Finland
Fascia plate sling or synthetic material for ptosis correction
+∞
10.4
10
*
9530/0-C70.0
ICD-O-3
Meningioma, NOS, of cerebral meninges
12.3
10.4
18
15
H47.1
ICD-10 Finland
Papilloedema, unspecified
33.2
10.4
13
*
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
4.2
10.3
39
99
I10
ICD-10 Finland
Essential (primary) hypertension
1.8
10.3
352
2693
D32.9
ICD-10 Finland
Benign neoplasm: Meninges, unspecified
17.1
9.9
15
9
C10AA01
ATC
simvastatin; oral
1.8
9.8
273
1947
H3603, E113
ICD-10 Finland
NA
9.8
9.8
19
20
103
Kela drug reimbursment
Diabetes, insulin-treated
1.9
9.7
175
1082
H3601, E103
ICD-10 Finland
NA
11.6
9.6
17
15
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
5.9
9.6
26
46
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.2
9.6
108
551
I69.0
ICD-10 Finland
Sequelae of subarachnoid haemorrhage
10.3
9.6
18
18
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
17.9
9.4
14
8
H47.2
ICD-10 Finland
Optic atrophy
17.9
9.4
14
8
A28
ICPC
Limited function/disability NOS
2.1
9.4
111
579
D32.06
ICD-10 Finland
Benign tumor of the meninges os petrosum or clivus area
+∞
9.4
9
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
9.4
262
1860
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
1.9
9.1
154
924
T90.5
ICD-10 Finland
Sequelae of intracranial injury
9.2
9.1
18
20
I60.0
ICD-10 Finland
Subarachnoid haemorrhage from carotid siphon and bifurcation
18.9
9.0
13
7
H3602, E113
ICD-10 Finland
NA
24.4
8.9
12
5
G35
ICD-10 Finland
Multiple sclerosis
8.1
8.9
19
24
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
2.6
8.7
66
278
B01AC30
ATC
platelet aggregation inhibitors excl. heparin - combinations
2.7
8.7
58
226
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
16.6
8.6
13
8
H3601, E113
ICD-10 Finland
NA
6.1
8.5
22
37
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
3.3
8.5
41
129
H36.00
ICD-10 Finland
Diabetic background retinopathy
7.5
8.5
19
26
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
5.2
8.4
25
50
I60.9
ICD-10 Finland
Subarachnoid haemorrhage, unspecified
6.0
8.4
22
38
N03AX14
ATC
levetiracetam; systemic
4.9
8.3
26
55
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
17.5
8.1
12
7
PA2YT
NOMESCO Finland
Cerebral artery PTA with stent
33.8
8.1
10
*
108
Kela drug reimbursment
Myasthenia gravis
33.8
8.1
10
*
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
6.7
7.9
19
29
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
13.3
7.9
13
10
SPAT1229
SPAT
Assessment of need for aid
2.5
7.8
60
254
E10.5
ICD-10 Finland
Type 1 diabetes mellitus, With peripheral circulatory complications
15.3
7.7
12
8
E10.2
ICD-10 Finland
Type 1 diabetes mellitus, With renal complications
15.3
7.7
12
8
A10AE05
ATC
insulin detemir; parenteral
3.0
7.7
44
156
AAL00
NOMESCO Finland
Endovascular occlusion of intracranial aneurysm
18.6
7.6
11
6
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.1
7.6
91
476
I60.7
ICD-10 Finland
Subarachnoid haemorrhage from intracranial artery, unspecified
25.4
7.6
10
*
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
9.0
7.6
15
17
E10.00
ICD-10 Finland
Insulin-dependent diabetes diabetic hypoglycemic coma
10.2
7.6
14
14
H53.1
ICD-10 Finland
Subjective visual disturbances
2.9
7.5
44
160
CKC12
NOMESCO Finland
Photocoagulation of retina
3.2
7.4
37
120
N02BE01
ATC
paracetamol; systemic, rectal
1.8
7.4
478
4197
S04.1
ICD-10 Finland
Injury of oculomotor nerve
81.1
7.4
8
*
H50.0
ICD-10 Finland
Convergent concomitant strabismus
81.1
7.4
8
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
13.6
7.4
12
9
215
Kela drug reimbursment
Diabetes, non-insulin-treated
1.8
7.4
146
916
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.0
7.4
97
528
H36.01
ICD-10 Finland
Diabetic maculopathy
7.0
7.3
17
25
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
5.3
7.3
21
41
F05
ICPC
Visual disturbance other
4.1
7.3
27
69
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.6
7.2
52
212
AA1BD
NOMESCO Finland
Extensive CT of head and brain
4.0
7.2
27
70
D32.0
ICD-10 Finland
Benign neoplasm: Cerebral meninges
20.3
7.1
10
5
109
Kela drug reimbursment
Multiple sclerosis
8.9
7.1
14
16
E11.3
ICD-10 Finland
Type 2 diabetes mellitus, with ophthalmic complications
3.8
7.1
28
76
H36.09*E10.3
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic retinopathy
10.2
7.1
13
13
E11.00
ICD-10 Finland
Non-insulin dependent diabetes diabetic hypoglycaemic coma
3.4
7.0
32
98
WX408
NOMESCO Finland
General anesthesy, balanced
1.8
7.0
150
964
T90
ICPC
Diabetes non-insulin dependent
1.8
6.9
138
866
CS494
NOMESCO Finland
Other visual field testing
4.8
6.8
21
45
G52.8
ICD-10 Finland
Disorders of other specified cranial nerves
40.5
6.8
8
*
C08CA01
ATC
amlodipine; oral
1.6
6.7
215
1546
XA800
NOMESCO Finland
Neuropsychological investigation
3.3
6.5
31
98
SPAT1263
SPAT
Sampling
1.6
6.5
230
1691
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
6.3
6.5
16
26
2507B
ICD-9 Finland
Diabetes mellitus, Diabetes with peripheral circulatory disorders[DIABETES MELLITUS CUM COMPLICAT ALIA ,TYYPPI I]
70.6
6.4
7
*
C03CA01
ATC
furosemide; systemic
1.6
6.4
182
1262
PA2LT
NOMESCO Finland
Endovascular closure of extensive brain aneurysm
14.5
6.4
10
7
L03AB07
ATC
interferon beta-1a; parenteral
14.5
6.4
10
7
SPAT1301
SPAT
No procedures
1.6
6.4
187
1307
SPAT1262
SPAT
Handing over of treatment supplies
1.8
6.4
115
698
G91.1
ICD-10 Finland
Obstructive hydrocephalus
18.2
6.3
9
5
A10BA02
ATC
metformin; oral
1.7
6.2
166
1133
H05.2
ICD-10 Finland
Exophthalmic conditions
27.0
6.2
8
*
S06.3
ICD-10 Finland
Focal brain injury
5.4
6.2
17
32
25000
ICD-8 Finland
Diabetes mellitus, Sine complicatione
4.1
6.2
22
55
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
1.8
6.1
119
741
205
Kela drug reimbursment
Chronic hypertension
1.6
6.1
179
1250
N08.39
ICD-10 Finland
Glomerular disorders in diabetes mellitus microalbuminuria
12.7
6.1
10
8
N18
ICPC
Paralysis/weakness
5.0
6.1
18
37
H36.03
ICD-10 Finland
Proliferative diabetic retinopathy
8.7
6.1
12
14
H3600, E103
ICD-10 Finland
NA
8.7
6.1
12
14
XCD10
NOMESCO Finland
Electrophysiological examination of eye
4.0
6.0
22
56
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
43
31
14.82
47.20
1.0
1.1
3.5
1.4
nmol/l
—
11
5
66
101
7.19
42.07
1.4
1.4
16.5
9.9
e6/l
0.35
49
81
66
101
7.19
42.07
1.4
1.5
1427.8
133.0
e6/l
1.07
50
83
39
39
10.60
34.81
1.0
1.0
—
—
—
0
0
35
30
12.30
34.55
1.0
1.0
—
—
—
0
0
42
49
9.12
33.49
1.1
1.1
—
—
—
0
0
302
1588
2.75
33.45
2.3
2.1
143.2
233.8
u/l
2.42
285
1493
41
48
9.07
32.60
1.1
1.1
—
—
—
0
0
34
33
10.84
30.92
1.1
1.1
51.8
43.7
mg/l
0.21
27
28
29
28
10.81
26.41
1.0
1.0
1.0
1.2
u/l
0.62
14
16
182
823
2.71
26.02
1.9
2.2
28.9
29.6
s
1.08
171
792
22
22
10.33
19.47
1.2
1.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
23
25
9.51
19.20
1.2
1.2
—
—
—
0
0
421
3018
2.21
18.87
8.0
4.9
7.1
6.8
mmol/l
2.66
402
2838
29
43
7.02
18.84
1.4
1.2
—
—
—
0
0
87
323
2.97
17.56
2.3
2.5
11.9
11.3
au/ml
—
5
15
133
617
2.47
17.31
9.5
7.2
1.4
1.3
mmol/l
0.17
106
485
132
618
2.44
16.80
9.6
7.2
5.1
5.1
kpa
0.15
125
592
132
619
2.44
16.74
9.6
7.1
12.4
12.0
kpa
0.32
125
596
63
211
3.21
15.12
1.6
2.2
33.8
39.0
u/l
1.40
51
187
17
18
9.68
14.38
1.2
1.2
—
—
—
0
0
326
2273
1.91
13.95
6.8
4.8
34.6
35.2
g/l
1.23
315
2103
101
455
2.46
13.82
1.9
3.3
66.8
66.2
g/l
0.35
92
415
22
35
6.48
13.36
1.4
2.7
—
—
—
0
0
355
2605
1.84
12.35
11.6
6.9
1.2
1.2
mmol/l
0.34
298
2208
120
618
2.17
11.91
2.0
1.9
—
—
—
0
0
103
504
2.25
11.58
10.9
7.9
120.1
120.1
g/l
0.01
97
489
120
626
2.14
11.50
2.1
1.9
—
—
—
0
0
327
2392
1.77
11.01
11.3
6.1
1.2
1.2
mmol/l
0.86
300
2164
153
898
1.93
10.51
2.0
1.9
—
—
—
0
0
95
469
2.21
10.41
3.3
2.0
359.2
376.5
nmol/l
0.40
89
432
124
687
2.00
10.02
11.2
6.0
1.1
1.0
mmol/l
1.71
118
632
12
14
8.72
9.37
1.1
1.1
—
—
—
0
0
12
14
8.72
9.37
1.1
1.1
—
—
—
0
0
73
340
2.30
9.17
11.5
6.6
25.1
24.5
mmol/l
0.58
67
320
32
104
3.19
8.09
1.5
1.7
4.9
6.1
iu/l
0.21
12
29
278
2060
1.63
8.06
5.0
3.9
47.1
38.8
ng/l
0.43
224
1514
347
2720
1.62
7.96
6.7
6.5
10.8
11.8
umol/l
0.88
326
2580
308
2363
1.60
7.59
5.3
4.0
—
—
—
0
0
11
15
7.45
7.57
1.1
1.1
—
—
—
0
0
11
7
15.96
7.25
1.1
1.1
—
—
—
0
0
273
2055
1.58
7.17
2.8
2.2
73.5
77.7
nmol/l
1.77
247
1814
11
16
6.98
7.17
1.0
1.1
—
—
—
0
0
10
5
20.29
7.15
1.1
1.4
—
—
—
0
0
256
1913
1.57
6.86
4.8
3.4
—
—
—
0
0
442
3744
1.62
6.81
4.8
4.1
14.5
13.0
mm/h
1.32
407
3419
114
695
1.78
6.71
10.8
6.5
104.1
104.1
mmol/l
0.01
108
677
217
1572
1.58
6.59
3.7
3.4
33.4
32.6
u/l
0.12
204
1494
222
1620
1.57
6.52
3.2
2.5
53.7
56.0
u/l
0.42
205
1508
18
46
4.00
6.48
1.1
1.1
—
—
—
0
0
10
15
6.76
6.33
1.1
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
41
176
2.42
6.21
3.0
3.2
0.3
0.4
u/ml
0.78
25
101
179
1254
1.60
6.20
3.0
2.4
—
—
—
0
0
311
2466
1.52
6.16
5.1
3.9
0.0
0.0
estimate
0.00
55
453
155
1050
1.63
6.15
1.7
1.7
1235.0
1176.6
nmol/l
0.26
118
784
10
8
12.68
6.10
1.2
1.3
—
—
—
0
0
451
3888
1.58
5.97
9.4
7.8
81.7
79.8
u/l
0.29
418
3634
9
6
15.19
5.91
1.1
1.3
—
—
—
0
0
49
233
2.20
5.88
1.8
1.9
3.2
2.9
ug/l
0.06
42
205
130
855
1.66
5.77
3.7
3.5
0.8
0.8
mmol/l
1.20
123
798
189
1366
1.55
5.64
5.9
4.1
0.0
0.0
estimate
0.00
55
439
27
100
2.78
5.50
2.2
1.3
5.8
10.7
u/l
1.71
21
76
353
2916
1.48
5.48
10.3
9.1
4.4
4.2
e9/l
1.29
323
2572
43
201
2.22
5.39
1.7
2.9
9.6
10.0
g/l
0.26
35
172
72
409
1.86
5.31
5.7
4.1
151.8
85.9
ng/l
1.30
67
365
159
1127
1.55
5.12
6.1
4.3
1.0
1.0
kg/l
0.39
21
162
10
19
5.33
5.05
2.4
2.6
588.9
798.2
u/ml
—
10
19
10
19
5.33
5.05
1.2
1.3
—
—
—
0
0
11
24
4.65
4.79
1.1
1.0
—
—
—
0
0
146
1031
1.54
4.75
4.9
4.0
429.0
330.8
ng/l
0.18
118
834
13
33
4.00
4.73
1.7
1.9
—
—
—
0
0
302
2470
1.43
4.64
6.4
5.3
0.0
0.0
estimate
0.00
57
455
194
1462
1.47
4.60
3.9
3.3
0.5
0.6
e6/l
0.02
150
1102
41
202
2.10
4.54
1.7
2.9
2.9
3.2
g/l
1.08
33
158
86
540
1.69
4.52
4.5
3.4
—
—
—
0
0
43
218
2.04
4.42
1.7
2.8
3.9
3.7
g/l
0.48
33
156
43
218
2.04
4.42
1.7
2.8
7.6
7.4
g/l
0.20
33
162
43
218
2.04
4.42
1.7
2.8
—
—
—
0
0
244
1933
1.43
4.41
5.5
4.1
—
—
—
0
0
303
2496
1.42
4.39
5.2
3.9
0.0
0.0
estimate
0.50
55
438
43
219
2.03
4.37
4.1
5.3
1.6
1.6
%
0.09
38
206
15
45
3.39
4.35
1.1
1.1
—
—
—
0
0
82
514
1.69
4.33
6.4
3.9
2.2
1.9
mmol/l
0.37
67
410
426
3734
1.44
4.32
4.8
3.8
14.9
14.9
pmol/l
0.05
392
3367
7
6
11.78
4.28
1.3
1.2
—
—
—
0
0
13
36
3.67
4.22
2.2
1.9
0.2
0.2
e9/l
0.24
13
29
80
502
1.68
4.21
2.3
2.4
4.8
6.9
ug/l
1.09
70
437
36
174
2.13
4.20
1.6
4.4
1.4
2.0
ratio
—
5
18
268
2176
1.41
4.15
2.1
2.0
91.7
93.9
pmol/l
0.32
136
1125
228
1802
1.42
4.11
3.7
3.5
2.4
2.4
mmol/l
1.11
199
1559
392
3403
1.41
4.06
6.7
4.7
226.2
3388.6
e6/l
1.48
12
67
209
1629
1.43
4.06
4.0
3.1
6.9
7.5
mmol/l
1.57
169
1350
498
4519
1.51
4.05
5.4
4.6
1.9
2.2
mu/l
0.56
457
4079
28
125
2.30
3.95
1.3
1.7
—
—
—
0
0
553
5147
1.65
3.91
29.7
18.3
139.4
139.6
mmol/l
1.43
542
5004
29
133
2.24
3.86
1.3
1.6
—
—
—
0
0
175
1333
1.43
3.83
2.6
2.2
3.1
3.2
mg/l
0.19
152
1137
32
154
2.14
3.79
1.7
1.5
0.4
0.1
iu/ml
—
10
29
553
5159
1.63
3.72
30.3
18.4
4.0
4.0
mmol/l
0.07
541
5015
155
1162
1.44
3.68
1.9
1.7
469.9
439.9
pmol/l
0.58
131
960
29
136
2.19
3.67
1.7
1.7
—
—
—
0
0
29
136
2.19
3.67
2.2
2.7
92.4
90.3
%
0.18
29
129
96
653
1.56
3.65
9.6
7.3
—
—
—
0
0
17
62
2.79
3.61
1.2
1.9
—
—
—
0
0
208
1648
1.39
3.61
5.3
4.0
20.0
9.0
mg/mmol
1.49
141
1051
535
4961
1.55
3.61
24.8
15.6
22.8
25.0
mg/l
1.00
455
3961
31
151
2.11
3.58
1.1
1.3
0.2
0.2
g/l
0.56
31
143
16
57
2.85
3.54
1.3
2.0
—
—
—
0
0
35
180
2.00
3.50
1.5
1.2
—
—
—
0
0
6
6
10.08
3.50
1.2
1.0
—
—
—
0
0
20
81
2.52
3.49
2.8
3.3
—
779.5
—
0
6
53
315
1.75
3.41
1.5
1.5
—
—
—
0
0
24
110
2.23
3.23
1.3
1.4
—
—
—
0
0
24
110
2.23
3.23
1.3
1.4
—
—
—
0
0
8
15
5.39
3.20
1.1
1.1
—
—
—
0
0
69
450
1.60
3.15
3.6
3.0
189.0
224.7
ng/l
0.38
60
412
167
1301
1.39
3.15
1.7
1.6
21.3
20.3
nmol/l
0.31
146
1091
31
160
1.99
3.10
1.2
1.3
1.2
1.2
g/l
1.11
31
152
210
1705
1.35
3.04
3.5
3.1
1695.5
1529.6
ng/l
0.18
178
1470
55
343
1.66
3.00
1.7
1.7
—
—
—
0
0
16
360
0.43
2.96
1.7
1.7
—
—
—
0
0
28
142
2.02
2.94
1.7
1.6
—
—
—
0
0
15
58
2.63
2.89
1.3
1.4
—
—
—
0
0
12
41
2.96
2.87
1.2
1.3
—
—
—
0
0
21
97
2.21
2.80
1.0
1.1
—
—
—
0
0
10
31
3.26
2.78
1.3
1.6
—
—
—
0
0
20
91
2.24
2.76
1.2
1.4
—
—
—
0
0
5
6
8.39
2.75
1.2
1.2
—
—
—
0
0
5
6
8.39
2.75
1.2
1.7
—
—
—
0
0
17
72
2.40
2.74
1.4
1.6
—
—
—
0
0
7
14
5.04
2.73
1.0
1.0
1911.9
1711.4
miu/ml
—
7
14
520
4859
1.42
2.73
5.4
4.7
6.3
6.0
mmol/l
3.95
474
4391
498
4621
1.38
2.71
8.2
6.1
43.5
40.4
mmol/mol
7.15
459
4277
6
10
6.05
2.70
1.2
1.0
—
—
—
0
0
19
86
2.25
2.66
1.3
1.6
—
—
—
0
0
13
49
2.69
2.63
1.3
1.6
—
—
—
0
0
62
413
1.56
2.61
2.4
2.9
62.6
62.6
ml/min/173m2
0.00
28
174
63
427
1.53
2.47
6.8
3.7
1.2
1.2
mmol/l
0.16
55
372
111
840
1.39
2.46
4.5
2.4
11.6
12.5
umol/l
0.81
100
772
32
182
1.80
2.44
3.1
3.3
—
—
—
0
0
15
64
2.38
2.40
1.2
1.5
—
—
—
0
0
98
729
1.41
2.40
4.7
2.5
20.5
22.5
%
0.65
77
620
354
3158
1.28
2.39
3.8
3.2
61.3
51.3
u/l
0.78
324
2935
165
1334
1.32
2.38
3.7
2.9
342.3
8119.4
umol/l
6.25
149
1143
119
917
1.37
2.36
3.0
2.9
0.9
1.0
e6/l
0.18
71
534
20
98
2.08
2.34
10.1
7.6
148.1
312.5
iu/ml
—
7
19
18
85
2.15
2.30
1.3
1.8
—
—
—
0
0
19
94
2.05
2.18
2.5
3.3
58.4
59.2
%
0.10
19
94
553
5271
1.43
2.16
14.3
10.8
26.3
25.5
u/l
0.47
530
5079
315
2797
1.25
2.11
2.9
2.8
—
—
—
0
0
39
246
1.62
2.09
1.8
2.0
1.5
1.5
g/l
0.13
31
220
34
207
1.68
2.09
1.5
1.8
—
—
—
0
0
18
89
2.05
2.07
1.8
2.8
4.4
4.5
e9/l
0.12
18
89
25
140
1.82
2.04
1.7
1.6
—
—
—
0
0
20
104
1.95
2.02
2.6
2.3
16.9
15.8
%
—
9
49
57
396
1.48
2.02
1.8
1.7
—
—
—
0
0
160
1316
1.29
2.01
1.9
1.6
1.4
1.4
mmol/l
0.08
136
1093
15
70
2.17
1.99
9.3
5.3
11.3
11.7
mg/l
0.16
15
65
13
57
2.31
1.99
1.2
1.1
1.4
1.7
u/ml
—
5
17
99
771
1.34
1.84
4.6
2.4
2.1
2.3
g/l
1.73
89
712
6
17
3.55
1.84
1.0
1.0
—
—
—
0
0
9
35
2.59
1.80
1.6
1.3
—
—
—
0
0
18
95
1.92
1.77
1.5
1.3
—
—
—
0
0
79
599
1.37
1.75
4.6
4.4
257.1
261.7
u/l
0.08
73
564
13
61
2.16
1.72
1.3
1.7
—
—
—
0
0
0
48
0.00
1.70
0.0
1.4
—
—
—
0
0
0
48
0.00
1.70
0.0
1.4
—
—
—
0
0
0
48
0.00
1.70
0.0
1.4
—
—
—
0
0
7
25
2.82
1.65
1.3
1.3
—
—
—
0
0
24
144
1.69
1.60
3.7
2.9
3.5
3.6
g/l
0.07
24
137
493
4673
1.26
1.58
4.8
4.1
1.4
1.3
mmol/l
1.84
445
4236
5
15
3.35
1.52
1.0
1.2
—
—
—
0
0
66
499
1.36
1.51
2.7
2.2
0.2
0.2
g/l
0.42
61
467
22
131
1.70
1.51
1.9
1.7
—
—
—
0
0
12
58
2.09
1.50
1.1
1.1
—
—
—
0
0
48
346
1.42
1.46
4.2
4.0
2.4
1.9
mmol/l
0.43
34
261
238
2114
1.20
1.44
3.9
2.7
149.7
135.8
ug/l
0.31
217
1932
19
111
1.73
1.40
1.4
1.5
—
—
—
0
0
5
17
2.96
1.36
1.4
1.8
—
—
—
0
0
5
17
2.96
1.36
1.4
1.8
—
—
—
0
0
0
37
0.00
1.34
0.0
2.3
—
13.3
—
0
37
16
90
1.80
1.34
2.6
2.0
196.2
4056.3
u/l
—
6
26
41
293
1.43
1.32
1.4
1.2
280.7
143.6
iu/ml
0.83
17
119
13
69
1.90
1.29
1.0
1.6
—
—
—
0
0
123
1040
1.23
1.22
3.1
3.0
2.5
2.5
mmol/l
0.82
107
902
6
129
0.46
1.17
1.0
1.1
—
9.1
—
0
12
5
20
2.51
1.15
2.0
5.7
—
—
—
0
0
563
5472
1.30
1.13
35.4
22.7
131.5
134.2
g/l
3.83
555
5378
11
58
1.91
1.12
1.4
1.6
60.2
60.9
%
—
6
44
503
4832
1.21
1.11
5.4
4.5
1.4
1.5
mmol/l
3.55
455
4400
5
21
2.39
1.09
1.4
1.7
—
—
—
0
0
37
271
1.39
1.07
3.9
2.6
0.8
0.7
%
1.22
37
264
506
4870
1.21
1.06
5.5
4.5
4.4
4.6
mmol/l
3.84
460
4468
11
60
1.85
1.03
2.1
2.5
—
—
—
0
0
7
34
2.07
1.03
6.0
3.4
—
—
—
0
0
46
355
1.32
0.98
2.8
2.2
10.2
12.8
nmol/l
1.34
40
314
19
124
1.55
0.98
1.6
1.4
—
—
—
0
0
486
4673
1.18
0.96
21.1
14.4
76.8
77.5
ml/min/173m2
0.24
420
3871
13
77
1.70
0.95
1.0
1.1
—
—
—
0
0
9
51
1.78
0.95
1.1
1.6
—
—
—
0
0
21
142
1.50
0.93
3.5
2.5
205.6
89.1
ug/min
0.59
13
80
6
28
2.15
0.91
1.5
1.4
—
—
—
0
0
6
28
2.15
0.91
1.5
1.4
—
—
—
0
0
6
28
2.15
0.91
1.0
1.5
1.2
3.7
u/field
—
6
19
9
152
0.59
0.89
1.0
1.2
—
—
—
0
0
9
152
0.59
0.89
1.0
1.2
—
—
—
0
0
13
79
1.66
0.88
1.2
1.1
81.8
17.1
iu/ml
—
5
16
515
4987
1.19
0.88
6.0
5.1
2.6
2.7
mmol/l
2.77
469
4543
11
64
1.73
0.86
34.0
6.5
8.4
6.8
mmol/l
0.84
11
52
6
31
1.94
0.84
1.0
1.1
—
—
—
0
0
6
31
1.94
0.84
1.0
1.1
—
—
—
0
0
11
65
1.70
0.82
1.3
1.6
—
—
—
0
0
6
32
1.88
0.82
1.0
1.1
—
—
—
0
0
6
32
1.88
0.82
1.0
1.1
—
—
—
0
0
6
32
1.88
0.82
1.0
1.1
—
—
—
0
0
6
33
1.83
0.79
1.5
1.3
—
—
—
0
0
71
597
1.21
0.78
3.2
2.9
5.9
9.3
umol/l
2.38
62
527
16
231
0.68
0.75
1.4
1.3
—
—
—
0
0
5
24
2.09
0.74
1.0
2.3
—
88860.8
—
0
5
7
39
1.80
0.72
1.1
1.2
—
—
—
0
0
30
229
1.33
0.72
1.7
2.0
—
—
—
0
0
199
1830
1.13
0.71
5.4
5.1
10.2
2.6
ug/l
0.46
175
1622
38
303
1.27
0.68
5.7
2.8
0.2
0.3
e6/l
0.95
38
296
18
128
1.42
0.66
1.5
1.9
—
—
—
0
0
17
120
1.43
0.65
2.1
1.8
33.6
41.0
nmol/l
1.01
17
114
455
4403
1.12
0.63
25.7
16.6
39.0
39.4
%
0.35
265
3043
5
30
1.67
0.61
2.0
1.4
1.0
1.0
g/l
—
5
30
13
88
1.49
0.61
2.1
1.9
154.5
233.4
pmol/l
1.83
13
81
0
21
0.00
0.60
0.0
1.7
—
—
—
0
0
0
23
0.00
0.58
0.0
1.1
—
—
—
0
0
82
722
1.16
0.57
1.4
1.5
—
—
—
0
0
6
37
1.63
0.55
1.0
1.3
—
—
—
0
0
6
38
1.58
0.54
1.0
1.3
—
—
—
0
0
416
4030
1.10
0.50
30.7
19.0
14.0
13.8
%
1.32
408
3957
21
163
1.30
0.49
1.6
2.0
—
—
—
0
0
96
869
1.12
0.46
3.3
3.2
3.3
2.2
e6/l
0.33
48
491
5
31
1.62
0.43
2.8
2.6
—
—
—
0
0
5
32
1.57
0.42
1.0
1.3
—
—
—
0
0
5
33
1.52
0.41
1.4
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
84
763
1.12
0.39
29.3
24.7
1.3
1.2
inr
0.09
13
103
5
36
1.39
0.38
1.2
1.4
—
62.0
—
0
5
17
213
0.79
0.37
1.0
1.0
—
—
—
0
0
15
120
1.26
0.30
1.9
1.3
—
—
—
0
0
15
120
1.26
0.30
1.4
1.4
—
—
—
0
0
156
1481
1.07
0.29
4.6
4.4
21.2
20.9
%
0.08
78
724
8
67
1.20
0.26
2.8
3.7
—
—
—
0
0
16
132
1.22
0.26
1.2
1.3
—
—
—
0
0
9
76
1.19
0.24
1.0
1.1
—
—
—
0
0
52
475
1.10
0.24
3.3
2.3
33.5
31.0
u/l
0.23
43
394
15
124
1.21
0.24
1.2
1.7
7646.9
20538.9
e6/l
—
10
93
5
38
1.32
0.23
1.0
1.1
—
—
—
0
0
5
40
1.25
0.22
1.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.9
—
76.8
—
0
10
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.8
—
—
—
0
0
19
165
1.16
0.19
1.7
1.8
3.8
3.1
mg/l
0.14
14
123
7
60
1.17
0.18
1.3
1.7
—
—
—
0
0
7
60
1.17
0.18
1.3
1.7
—
—
—
0
0
7
60
1.17
0.18
1.3
1.7
—
—
—
0
0
7
61
1.15
0.17
1.1
1.0
—
—
—
0
0
10
82
1.22
0.17
1.0
1.3
—
—
—
0
0
8
70
1.14
0.16
1.0
1.5
—
—
—
0
0
8
71
1.13
0.16
1.0
1.5
—
—
—
0
0
8
71
1.13
0.16
1.0
1.5
—
—
—
0
0
103
1068
0.96
0.13
2.9
3.0
0.7
0.8
ug/l
0.61
72
716
32
342
0.93
0.11
1.5
2.0
—
—
—
0
0
106
1030
1.04
0.10
1.3
1.2
1.0
1.8
u/ml
0.65
28
262
75
775
0.96
0.09
1.3
1.2
1.1
11.7
u/ml
4.39
23
287
6
58
1.03
0.08
1.0
1.2
—
—
—
0
0
6
58
1.03
0.08
2.0
1.3
0.8
0.6
nmol/l
—
6
51
49
511
0.96
0.08
1.5
1.7
1.5
1.5
%
0.03
40
438
113
1103
1.03
0.08
1.8
1.7
1.3
1.3
mg/l
0.10
85
862
32
303
1.06
0.08
1.4
1.9
—
—
—
0
0
65
629
1.04
0.07
1.3
1.5
—
—
—
0
0
14
130
1.08
0.04
1.4
1.6
—
—
—
0
0
57
584
0.97
0.04
3.4
4.2
10.3
33.4
ug/l
0.87
48
492
11
119
0.92
0.04
1.1
1.4
—
—
—
0
0
12
129
0.93
0.03
7.3
4.1
30.2
27.1
mg/l
—
7
82
67
660
1.02
0.02
5.4
4.6
32.3
31.9
%
0.11
54
437
14
135
1.04
0.00
1.1
1.3
—
—
—
0
0
12
117
1.03
0.00
1.4
1.5
—
—
—
0
0
82
816
1.01
0.00
1.3
1.2
32.8
39.1
iu/ml
0.17
16
253
23
229
1.00
0.00
2.7
3.4
18.1
5909.2
u/ml
0.77
18
201
7
70
1.00
0.00
1.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
52.0
—
0
5
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
7
69
1.01
0.00
1.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
70.8
—
0
6
5
52
0.96
0.00
1.2
2.5
1.6
2.6
u/field
—
5
18
7
71
0.99
0.00
1.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
7
72
0.97
0.00
1.9
2.3
2.6
60.7
u/ml
—
7
67
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
19.3
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint H7_PARASTRA3 and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_PARASTRA3 | 1.566 [1.37, 1.79] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.183 |
During the follow-up period (1.1.1998 — 31.12.2019), 692 out of 1999 females with H7_PARASTRA3 died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_PARASTRA3 | 1.569 [1.36, 1.81] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.022 |
During the follow-up period (1.1.1998 — 31.12.2019), 689 out of 1924 males with H7_PARASTRA3 died.
Mortality risk
Mortality risk for people of age
years, who have H7_PARASTRA3.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.185% | 0.384% |
| 5 | 0.985% | 1.951% |
| 10 | 2.446% | 4.668% |
| 15 | 4.765% | 8.998% |
| 20 | 8.383% | 15.595% |
Relationships between endpoints
↥Index endpoint: H7_PARASTRA3 – Third [oculomotor] nerve palsy
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data